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background:  Management of chest pain patients with an initial negative troponin but an elevated copeptin level is unclear. We hypothesized that 
a second copeptin measurement two hours after presentation would help risk-stratify these patients.
methods: The multi-center CHOPIN trial enrolled 2071 acute chest pain patients. 494 subjects with an initial negative troponin and elevated 
copeptin (>14 pmol/L) were included in this study. Copeptin and troponin levels were rechecked at 2 hours and the final diagnosis of acute 
myocardial infarction (AMI) was made by two independent, blinded cardiologists.
results: Of the 494 patients analyzed, 378 (76.5%) had a persistently elevated copeptin at 2 hours and 116 patients (23.5%) had a copeptin that 
fell below the cutoff of 14 pmol/l. The AMI rate was 6.1% when the second copeptin was elevated compared to 0% when the second copeptin was 
not (p=.006), yielding a sensitivity of 100%. This strategy identified 23.5% of patients with an intermediate risk who could be ruled out for AMI while 
still in the ED. In contrast, a second troponin measurement had a sensitivity of 74%.
Conclusions: A negative second copeptin drawn 2 hours after presentation demonstrated 100% sensitivity for AMI, allowing for effective rule out 
in this intermediate risk cohort. This strategy identified nearly 25% of intermediate risk patients who could be considered for discharge, creating the 
potential for a significant reduction in the number of unnecessary chest pain admissions.
 
